Estimate The Effect Of Repeat-Dose Rifampin On The Pharmacokinetics Of CP-690,550 In Healthy Volunteers

Pfizer

Status and phase: Completed; Phase 1

Conditions: Healthy

Treatments: Drug: Tasocitinib (CP-690,550) plus Rifampin

Study type: Interventional

Funder types: Industry

Identifiers

NCT01204112

A3921056

Details and patient eligibility

About

The current study is designed to estimate the effect of rifampin (600 mg orally every 24 hours for 7 days) on pharmacokinetics of single 30 mg dose (CP-690,550) in normal healthy volunteers

Enrollment: 12 patients

Sex: All

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy male and/or female subjects (of non-childbearing potential)

Exclusion criteria

• Clinically significant disease or condition
• Recent serious infection

Trial design

Primary purpose: Basic Science

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

12 participants in 1 patient group

Tasocitinib (CP-690,550) plus Rifampin

Experimental group

Treatment:

Drug: Tasocitinib (CP-690,550) plus Rifampin